Patents Examined by Ganapathy Krishnan
  • Patent number: 10064883
    Abstract: The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumor activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: September 4, 2018
    Assignee: GUERBET
    Inventors: Boris Guiu, Mathieu Boulin, Jean-Pierre Cercueil
  • Patent number: 10064886
    Abstract: Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: September 4, 2018
    Assignee: NOVINTETHICAL PHARMA SA
    Inventors: Miguel Angel Alonso Cohen, Michele Giuseppe Di Schiena, Marco Di Fulvio
  • Patent number: 10058566
    Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerizing factor activity inhibitors and actin-aggregation inhibitors.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 28, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
    Inventors: Jian Ding, Jing Ai, Yi Chen, Xun Huang
  • Patent number: 10046046
    Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
  • Patent number: 10046003
    Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: August 14, 2018
    Assignee: INDUS BIOTECH PRIVATE LIMITED
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 10039776
    Abstract: The present invention relates to a hepato-protective beverage composition comprising a potable liquid, a primary hepato-protective agent comprising 18?-Glycyrrhizin or 18?-Glycyrrhizin or a combination thereof, and a complimentary hepato-protective agent comprising sugar or sugar alcohol or a combination thereof. The combination of effective amounts of the primary and complimentary hepato-protective agents provides hepato-protection and reduced toxicity caused by consumption of alcoholic beverages. The present invention also provides a beverage additive comprising these hepato-protective agents designed to be mixed with a potable liquid, providing the same beneficial results.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: August 7, 2018
    Inventor: Harsha Chigurupati
  • Patent number: 10030040
    Abstract: The invention relates to processes for preparing (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside and compositions comprising the same.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: July 24, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Melpo Christofidou-Solomidou, Kyriacos C. Nicolaou, Roman A. Valiulin, Nicholas Simmons, Philipp M. Heretsch
  • Patent number: 10023659
    Abstract: The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Dilafor AB
    Inventors: Per-Olov Eriksson, Erik Yngve Holmer
  • Patent number: 10022389
    Abstract: New drugs useful in the prevention or treatment of constipation are provided, in which SGLT1 inhibiting compounds, in particular, a 4-isopropylphenyl glucitol compound represented by the following formula (I), or pharmaceutically acceptable salts thereof are contained as an active ingredient:
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 17, 2018
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuke Yamamoto, Fusayo Io, Koji Yamamoto
  • Patent number: 10022393
    Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: July 17, 2018
    Assignee: SYNEDGEN, INC.
    Inventors: Shenda M. Baker, William P. Wiesmann
  • Patent number: 9962351
    Abstract: Disclosed is a new function of a small molecule metabolite glutamine. The small molecule can improve sensitivity of bacteria including antibiotic-resistant bacteria to antibiotics. Also disclosed is an application of glutamine in combination with glucose in improving sensitivity of bacteria to antibiotics.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: May 8, 2018
    Assignee: SUN YAT-SEN UNIVERSITY
    Inventors: Xuanxian Peng, Hui Li, Xianliang Zhao
  • Patent number: 9925310
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 9919060
    Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 20, 2018
    Assignee: University Court of the University of Dundee
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Patent number: 9913854
    Abstract: Provided herein are methods for inducing cell death in a gram positive bacterium and methods for reducing the proliferation of a gram positive bacterium that include contacting a gram positive bacterium with a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are methods of treating a subject having a gram positive bacterial infection that include administering to a subject having a gram positive bacterial infection a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are compositions containing a dye (e.g., an azo dye) and a TarO inhibitor, and kits containing at least one of these compositions.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 13, 2018
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Michael S. Gilmore, Takashi Suzuki
  • Patent number: 9907814
    Abstract: A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 6, 2018
    Assignee: Henry Ford Health System
    Inventor: Hani N. Sabbah
  • Patent number: 9889204
    Abstract: The disclosure provides, inter alia, polymeric antibiotic compounds such as modified chitosans and methods of use thereof.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: February 13, 2018
    Assignee: The Regents of the University of California
    Inventors: Young Jik Kwon, Julius Edson
  • Patent number: 9879041
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 30, 2018
    Assignees: Victoria Link Limited, University of Liverpool
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Patent number: 9846163
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 9782386
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: October 10, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9765084
    Abstract: A process for the production of a refined dianhydrosugar-containing product is disclosed. The process includes controlled continuous crystallization of the dianhydrosugar-containing product to produce a solution saturated with the dianhydrosugar. The saturated solution is mechanically separated, for example by centrifugation, and the crystalline product is washed. The only solvent used is water. The dianhydrosugar-containing product is upgraded to at least 99.8% purity and recovery is 95% or greater. Recrystallization of the dianhydrosugar of 99.8% purity results in an ultra pure product containing at least 99.99% dianhydrosugar.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: September 19, 2017
    Assignee: Iowa Corn Promotion Board
    Inventors: Charles Guthrie Moyers, James Kermit Withrow, John Leonard Stephens